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Respirafovy Failure Unit, Depavtnzent of Medicine, Avistofle University of Thessaloniki, Greece 
To compare the effects of salmeterol, an adrenergic drug, and ipratropium bromide, an anticholinergic drug, on 
breathlessness and gas exchange during exercise in patients with chronic obstructive lung disease (COPD), we 
performed a progressive treadmill exercise test on 15 patients on 3 days (24 h apart), after inhalation placebo, 
ipratropium bromide (120,~g) or salmeterol (5Opg) in a randomized fashion. Dyspnoea during exercise was 
evaluated from the regression slope between Borg scale (BS) scores and distance walked each minute on the 
treadmill. The regression was expressed as the distance walked at BS score 5, the threshold load of dyspnoea (TLD) 
and breakpoint load of dyspnoea. During and after the exercise, oxygen saturation was monitored by pulse oxymeter 
and we measured the lower SaO, during exercise and the recovery time of SaO, after exercise. 
In comparison to placebo inhalation we found the same small but significant improvement in airflow limitation 
after salmeterol or ipratropium inhalation, also the distance walked on treadmill increased after bronchodilators. 
After bronchodilators the magnitude of oxyhaemoglobin desaturation with exercise was similar to that observed 
after placebo but the duration of the recovery from sustained SaO, desaturation after exercise was shorter to the 
same extent as after ipratropium or salmeterol. Dyspnoeic sensation, when assessed by the TLD and by the distance 
walked at BS score 5, was decreased after salmeterol and after ipratropium bromide to a similar extent. 
We conclude that the salmeterol, when given in conventional doses, produces significant improvement in the 
airway obstruction in the recovery of postexercise HbO, desaturation and in dyspnoeic sensation in patients with 
COPD, effects which were similar to those observed after inhalation of the anticholinergic agent ipratropium 
bromide. 
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Introduction 
A large number of trials have compared anticholinergic 
drugs to other bronchodilators in patients with stable 
chronic obstructive pulmonary disease (COPD) (l-5). 
Some trials that have employed conventional doses of each 
agent show that an anticholinergic agent results in more 
bronchodilation than an adrenergic agent in this patient 
population. The finding is surprising and contrasts with 
studies in asthma patients which show that adrenergic 
agents are more effective bronchodilators. The different 
order of efficacy of the two classes of bronchodilators is 
confirmed by a number of studies in which asthmatic and 
bronchitic group have been studied with both drugs (5). 
Anticholinergic agents also have a rather small effect on gas 
Received 24 October 1997 and accepted in revised form 18 May 
1998. 
Correspondence should be addressed to: D. Patakas, Respiratory 
Failure Unit, George Papanikolaou Hospital, Exohi, Thessaloniki, 
Greece. 
0954.6111/98/091116+06 $12.00/O 
exchange. Neither atropine nor its quaternary ammonium 
congeners lower the PaO, even in hypoxaemic patients with 
COPD (6). 
Several studies have shown that there is a relatively poor 
correlation between the exercise tolerance of patients with 
COPD and their level of pulmonary function. In general, 
the correlation coefficient between any measure of pulmon- 
ary function and the exercise tolerance is about 0.60, which 
indicates that only about 36% of the variance in the exercise 
tolerance can be explained by the level of pulmonary 
dysfunction (7). Thus it is possible that the administration 
of bronchodilators drugs could not improve the exercise 
tolerance of patients with COPD in spite of their bron- 
chodilating effect. To our knowledge, however, little infor- 
mation is available as to the effects of bronchodilator 
agents on dyspnoea during exercise in COPD. Teramoto 
et al. (8) found that inhaled oxipropium bromide produces 
improvement both in dyspnoea during exercise and in 
exercise performance in stable COPD. On the other hand, 
Leitch et al. (9) reported that 12-min walk distance in 
COPD could not be influenced by ipratropium bromide 
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TABLE 1. Anthropometric and physiologic data (on selection day) 
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DC0 FEV,” 
FVC FEV, knax511 (% predicted) (postbroncho- 
Age Ht (% predicted) (% predicted) (Y/O predicted) j;Imax50 ml min-’ dilation) 
No. year m Treatment 1 1 IS-’ 1s --I mmHg - ’ 1 
1 64 1.69 B, C 1.61 (43) 0.77 (27) 0.19 (4) 4.00 9.1 (47.2) 0.83 
2 63 1.67 B, T 1.71 (47) 0.70 (24) 0.35 (9) 2.30 7.2 (57.1) 0.71 
3 66 1.68 B, T, C I.98 (54) 0.75 (26) 0.35 (9) 2.06 7.4 (55.1) 0.81 
4 47 1.73 B 2.68 (61) 1.45 (40) 0.85 (21) 3.15 11.7 (61.0) 1.57 
5 62 1.60 B, C 1.66 (51) 0.80 (30) 0.29 (7) 2.37 8.6 (58.0) 0.85 
6 65 1.78 B; C 2.11 (50) 1.37 (42) 0.94 (24) 4.31 11.5 (62.3) 1.51 
7 62 1.64 B, C, T 1.70 (61) I.01 (46) 0.66 (19) 3.36 6.3 (52.1) 1.15 
8 70 1.70 B, C 1.57 (43) 0.92 (33) 0.55 (14) 2.78 8.6 (54.1) 1.01 
9 60 I.65 B; T 1.34 (43) 0.77 (33) 0.46 (13) 2.10 4.2 (41.2) 0.85 
10 74 I.62 B, C 1.56 (51) 0.57 (24) 0.27 (7) 2.92 5.8 (44.2) 0.65 
11 64 1.68 B, C, T 2.25 (64) 1.12 (56) 0.51 (14) 3.82 6.3 (45.2) 1.25 
12 66 1.65 B 1.69 (49) 1.05 (35) 0.74 (19) 2.23 7.0 (60.1) 1.20 
13 72 1.50 B 2.03 (78) 1.12 (19) 0.61 (19) 2.80 7.0 (50.0) 1.27 
14 77 I.68 B, C 1.61 (56) 0.92 (43) 0.73 (22) 3.09 5.7 (44.3) 1.01 
15 51 1.76 B, T 2.09 (49) 0.75 (27) 0.39 (9) 3.58 12 (61.0) 0.70 
“FEVI after inhalation of 4 puffs (200,~g) salbutamol. 
Ht, heights; B, inhaled bronchodilators; C, corticosteroids; T, theophylline. 
administration. Tobin et al. (10) reported that the cycle 
ergometer exercise capacity was increased in COPD after 
ipratropium, but not after fenoterol administration. 
Salmeterol is a rather new long-acting, effective, selective 
&agonist, the safety and potency profile of which com- 
pares very favourably with those of other /$-agonists 
(11-14). The effects of salmeterol on exercise performance, 
and dyspnoea sensation of patients with COPD were 
studied. 
The aim of this study was to examine and compare the 
effects of an anticholinergic drug, ipratropium bromide, on 
exercise performance and breathlessness of patients with 
chronic obstructive lung disease, to those of salmeterol, an 
adrenergic long-acting agent. 
Materials and Methods 
SUBJECTS 
Fifteen patients (age 64.6 + 7.2 years) with stable COPD 
participated in the study. To be included in this study 
patients were required to have a forced expiratory volume 
in 1 s (FEV,) less than 65% of predicted, less than 20% 
reversibility on P-adrenergic inhalation and diffusing capac- 
ity of the lung for CO (Dco) no more than 65% of predicted 
normal value. All patients were in a stable condition for at 
least 1 month; no patient was taking sedative drugs and all 
continued taking their usual treatment. 
Patients were excluded if they had coronary heart disease, 
left ventricular dysfunction, severe hypertension, disease of 
major organ system such as diabetes, renal failure, or 
neuromuscular disease that affected exercise performance. 
lnformed consent was obtained from ail subjects prior to 
entry into the study. The protocol was approved by our 
institutional review board. 
Demographic and pulmonary function data of our 
patients are presented in Table 1. 
STUDY DESIGN 
On a screening day the patients had spirometry before and 
after inhalation of 4 puffs (200 pg) salbutamol to ascertain 
if they met our study criteria (Table 1). The patient was 
then familiarized with the Borg scale (BS) (15) and the 
perceived dyspnoea treadmill exercise test (16). Patients 
were also informed to not take theophylline and anticholin- 
ergic compounds for 48 h before the study and no inhaled 
bronchodilators in the morning of the study days. 
The study was conducted on three separate days 24 h 
apart. Early in the morning subjects underwent a control 
pulmonary function test. As spirometric indices we chose 
the best of three maximal flow volume curves obtained 
using a Jaeger Transfersreen II spirometer. Measurements 
were made on forced vital capacity (FVC), FEV, and 
forced maximal expiratory (pE,,) and inspiratory (ii,,,) 
flows at 50% of FVC. After completing the control studies 
the subjects inhaled from a spacer (Volumatic, Glaxo) six 
puffs placebo or six puffs ipratropium bromide (12Opg) or 
two puffs salmeterol(50 pug). The order of the treatment was 
randomly distributed. Pulmonary function tests were 
repeated 30 min after drug inhalation and then a progres- 
sive incremental exercise test was performed on a treadmill. 
During the exercise test patients walked on a horizontal 
treadmill with a logarithmic increase in speed each minute 
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TABLE 2. Spirograms before and after inhalation placebo, ipratropium or salmeterol (mean + SD) 







FE,, (1 s - ‘) 
before 
after 
ii,,, (1 s - ‘) 
before 
after 
1.83 f 0.34 
1.83 zt 0.33 
0.94 + 0.25 
0.95 i 0.24 
0.52 f 0.22 
0.55 f 0.23 
3.03 + 0.74 
3.14 + 0.77 
169 i 0.40 
2.08 f 0.32** 
0.91 + 0.25 
1.12 + 0.35” 
0.53 zk 0.26 
0.64 f 0.37 
2.84 z!z 0.59 
3.41 + 0.73” 
169 % 0.36 
2.06 i 0.31*” 
0.89 i 0.26 
1.13 3~ 0.24” 
0.51 rt 0.23 
0.64 + 0.25 
2.16 i 0.67 
3.42 i 0.92* 
P values refer to comparisons between drugs and placebo ("P~0.05; **P<O,Ol). 
&O~ middle maximal expiratory flow. 
V i5,,, middle maximal inspiratory flow. 
to exhaustion (1.2, 1.8, 2.5, 4.4, 5.9, 8.0 km h- ‘). At the 
end of each minute, patients scored breathlessness on a 
lo-cm visual BS (dyspnoea: nothing at all to intolerable). 
The breathlessness score was then plotted against the 
distance walked (17). There were significant positive linear 
correlation between the dyspnoea expressed in BS and the 
distance walked in metres (m) in all patients (PcO.05). 
From these correlations we introduced three parameters for 
the quantitative assessment of dyspnoea: (1) the BS slope, 
which expressed as the distance walked at breathlessness 
score 5; (2) the break load of dyspnoea (BLD), which was 
expressed as the total distance walked in m and (3) the 
threshold load of dyspnoea-TLD (the distance walked on 
the treadmill with breathlessness score zero), which was 
expressed by the intercept of the regression line. The three 
parameters and the maximum score on Borg’s scale with 
peak exercise (BS,,,) were compared on the 3 study days. 
summarized in Table 2. We found no statistically significant 
differences between the initial FVC, FEV,, $‘nsO, pr’,,, 
values, before placebo or salmeterol or ipratropium inhala- 
tion. We found no changes in these parameters after 
placebo. After inhalation of ipratropium bromide and 
salmeterol there was a small but statistically significant 
improvement in FVC, FEV, and ?rZO values. When we 
compared the posttreatment values of FVC, FEV,, br,, 
and kn,,, we found no difference; the bronchodilating effect 
of salmeterol was similar to that of ipratropium bromide. 
Arterial oxygen saturation (SaO,) was continuously 
monitored before, during and after the exercise test with a 
pulse oxymeter (Criticon, Johnson-Johnson). Rest SaO, 
was determined before exercise and nadir SaO, was deter- 
mined as the minimum value that was observed during 
exercise. We also measured the recovery time, which was 
the time in seconds needed for SaO, recovery from its nadir 
at the end of exercise to the pre-exercise value. Rest SaO,, 
nadir SaO, and SaO, recovery time were compared after 
placebo, salmeterol and ipratropium. 
The resting SaO, after ipratropium or salmeterol was not 
different from that after placebo. Furthermore, nadir SaO, 
during exercise, following inhalation of bronchodilators 
was not different from the nadir SaO, recorded during 
exercise after placebo inhalation (Table 3). In contrast, the 
SaO, recovery time after ipratropium or after salmeterol 
was significantly shorter than after placebo administration. 
The SaO, recovery time was shorter after ipratropium that 
after salmeterol, but this difference was not significant. 
Statistical analysis was performed using Student’s paired 
t-test for paired data; PcO.05 was accepted as statistically 
significant. Data were presented as mean f standard 
deviation (SD). 
Results 
In all patients there was a close linear relationship 
between distance walked on treadmill and dyspnoea sensa- 
tion expressed in BS, after inhalation of placebo, salmeterol 
or ipratropium. From these correlations we have calculated 
four parameters (BLD, distance walked at BS score 5, 
TLD, BS,,,), for the quantitative assessment of dyspnoea. 
The changes in the dyspnoea indices during exercise after 
inhalation of placebo, ipratropium and salmeterol are 
shown in Table 4. The distance walked (BLD, m) increased 
statistically significantly after ipratropium and after salm- 
eterol. The TLD did not show drastic change after inhala- 
tion of ipratropium but was significantly increased after 
salmeterol (P<O.O5). Both drugs improved the distance 
walked at BS score 5. The BS,,, score during exercise, did 
not improve significantly after ipratropium or salmeterol 
treatment. 
Lung function measurements during the 3 days of the The mean heart rate (HR) after placebo at rest was 
study, before and after placebo or drugs administration, are 83 & 15.5 and after exercise 134.8 XIZ 12.2 beats min- ‘, the 
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TABLE 3. Arterial oxygen saturation (SaO,) with rest and exercise, before and after inhalation of 
placebo, ipratropium or salmeterol and their recovery time of SaO, (mean & SD) 
Placebo Ipratropium Salmeterol 
Rest SaO, (%) 93.5 z!z 2.5 94.1 i 26 94.1 f 2.7 
Nadir exercise SaO, (%) 85.5 I’C 8.6 86.7 zt 8.1 86.4 zk 7.7 
A Sat (%) 8.13 & 7.3 7.46 zk 6.3 7.1 zt 6.1 
Recovery time of SaO, (s) 114.4 & 53.1 66.6 * 33.4** 726 * 31.9x 
P values refer to comparisons between drugs and placebo (*P<O.O5; **P<O.Ol). 
TABLE 4. Dyspnoea indices during exercise after inhalation placebo, ipratropium, or salmeterol 
(mean f SD) 
Placebo Ipratropium Salmeterol 
BLD (m) 270.4 rt 73.1 350 f 67.3”” 366.5 dc 78,6** 
Distance walked at BS score (5 (m) 176.2 * 59.9 237 S 74.2” 248.2 rt 92,3* 
TLD (m) 42.9 rt 60.8 70.8 f 61.8 80.8 568.1” 
%mx 8.26 rt 1.09 7.8 zt 1.59 7.8 z!c 1.61 
BLD, Breakpoint load of dyspnoea: BS, Borg scale; TLD, threshold load of dyspnoea; BS,,,, the 
maximum score on Borg scale during exercise. P values refer to comparisons between drugs and 
placebo (*P<O.O5; ** P<O.Ol). 
respective values after ipratropium were 78.9 i 14.8 and 
132.6 5 15.4 and after salmeterol 80.4 f 14.4 and 
133.4 f 18.4 beats mini. The blood pressure (BP) after 
placebo at rest was 132 i 13 over 82 i 5 mmHg and the 
maximum during exercise 175 & 17 over 89 & 96 mmHg. 
After ipratropium the BP was at rest 125 i 14 over 81 i 7 
and during exercise 174 i- 9 over 92 % 7. The concomitant 
values after salmeterol were 128 % 126 over 76 rt 7 and 
175 % 11 mmHg over 91.3 f 7 mmHg. The values of BP 
and HR after salmeterol or ipratropium were not 
statistically significantly different from those after placebo. 
It is important to notice the absence of significant cor- 
relations between the changes in pulmonary function 
parameters (FVC, FEV,, vnsO, tit50 nadir exercise SaO,, 
recovery time of SaO,) observed after salmeterol or ipra- 
tropium and the improvements of dyspnoae indices.: Also 
we found no statistically significant differences in pulmon- 
ary function parameters, in dyspnoea indices and in 
haemodynamic parameters recorded after the ipratropium 
and salmeterol treatment. 
In addition, no adverse effects after the administration of 
salmeterol or placebo were observed in patients in the 
present study. 
Discussion 
Although patients with COPD do not respond to broncho- 
dilators as dramatically as do asthmatic patients, some 
increase in the FEV, and a reduction in dyspnoea are nearly 
always achieved on the administration of bronchodilator 
agents. A large number of trials have compared anticholin- 
ergic drugs to other bronchodilators in stable COPD (5). 
Trials that have employed conventional doses of each agent 
almost universally show that anticholinergic agents result in 
more bronchodilation than adrenergic agents. In this 
patient population this finding is surprising and in contrast 
with studies in asthmatic patients, which show that adren- 
ergic are more effective bronchodilators. However, this 
efficacy of anticohlinergic agents in COPD is probably due 
to the difference in the optimal dose of bronchodilator, 
since in studies which have employed large or sequential 
doses of each class of agent the bronchodilating effects were 
similar (18). In the present study we found that after a 
single treatment of ipratropium bromide (12Opg) or 
salmeterol (5Opg) the bronchodilatory effect was similar. 
The decrease in SaO, during exercise in COPD is consid- 
ered to result from ventilation perfusion mismatching, the 
lotiering of central venous SaO, or from diffusion limi- 
tations (19,20). After salmeterol or ipratropium bromide 
‘administration the magnitude of oxyhaemoglobin desatura- 
tion with exercise followed a pattern similar to that which 
was observed after placebo inhalation. Therefore, it sug- 
gests that inhaled salmeterol or ipratropium bromide, has 
little effect on gas exchange both at rest and during exercise 
in COPD patients. It is interesting that the duration of the 
recovery from sustained oxyhaemoglobin desaturation after 
exercise following ipratropium was similar to that after 
salmeterol, but both were significantly shorter when com- 
pared, to the recovery time of SaO, after exercise following 
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placebo. The cause of improvement of postexercise oxyhae- 
moglobin desaturation after bronchodilators inhalation 
could not be explained from our data. Teramoto et al. (8) 
suggested that the improvement of postexercise oxyhaemo- 
globin desaturation after oxiproprium bromide (a new 
anticholinergic agent) inhalation is due to a lower ventila- 
tory equivalent for oxygen uptake after exercise. They also 
postulated that increased cardiac output following exercise 
tests after oxiproprium administration and the increase in . 
blood flow improve the V/Q inequality. Furthermore, the 
improvement of airflow limitation after bronchodilators 
may contribute to early recovery from exercise induced 
oxyhaemoglobin desaturation. 
Exertional dyspnoea is a common and often incapacitat- 
ing symptom in patients with advanced COPD. In the 
present study we examined and compared the change in the 
dyspnoeic sensation during exercise after inhalation pla- 
cebo, ipratropium bromide or salmeterol. Despite exercis- 
ing for longer periods after inhalation of ipratropium or 
salmeterol, our patients had, at maximal exercise, BS,,, 
identical to those recorded at maximal exercise after pla- 
cebo. There was a significant increase in the distance walked 
on the treadmill after bronchodilators, but at these higher 
levels of exercise COPD patients terminated their task when 
they felt dyspnoea of the same maximal intensity as when 
taking the placebo. For the above reason the improvement 
in exertional dyspnoea after bronchodilators was not ascer- 
tained in COPD patients using score of BS,,, alone. On the 
contrary, consistent results were obtained as to dyspnoeic 
sensation during exercise in the COPD patients, when we 
assessed the dyspnoea using the TLD and the distance 
walked at BS score 5. In comparison with placebo, both 
parameters improved after salmeterol and the second 
after ipratropium inhalation. Also we found that the effect 
of salmeterol was similar to that of ipratropium when 
dyspnoeic sensation during exercise was assessed using 
these parameters. 
The mechanism of the decrease in dyspnoea during 
exercise following salmeterol or ipratropium bromide 
administration is not clear. Relief of breathlessness can be 
achieved with various bronchodilators in the presence of 
only a small improvement in FEV,, i.e. < 15% (23-25). The 
small improvement in airflow obstruction can produce an 
increase in maximal breathing capacity (MBC) and may 
reduce the sense of effort in breathing during exercise by 
decreasing the ventilatory index (minute ventilation 
expressed as fraction of maximal breathing capacity, kE/ 
MBC). 
The patients with COPD have an increased cholinergic 
tone, which may be responsible for the impaired pulmonary 
function at rest (25). Since ipratropium bromide may 
induce smooth muscle relaxation by modulating the affer- 
ent pathway of the vagal reflex, this may contribute to the 
reduction in the airway resistance during exercise. Stimu- 
lation of vagal afferent nerve ending in the airways and the 
lung have, in animals, effects on ventilation (26) but their 
role in mediating respiratory sensation in our patients is not 
clearly proven. Salmeterol, an adrenergic bronchodilating 
agent, not acting on airways by stimulation of vagal 
afferent nerve endings, had a similar effect on breathlessness 
sensation during exercise to ipratropium in our COPD 
patients and it is logical to assume that this mechanism, if it 
exists, is not unique. 
We conclude that the inhaled adrenergic agent sal- 
meterol, when given in conventional doses, produces 
significant improvements in the airflow obstruction, in the 
recovery from postexercise oxyhaemoglobin desaturation 
and the dyspnoeic sensation in patients with COPD; effects 
which were similar to those produced after the inhalation of 
the anticholinergic agent ipratropium bromide. The equiva- 
lent action of two drugs, exerting their bronchodilating 
effects acting in different neurohumoral mechanisms, indi- 
cates that the change in respiratory mechanics is the import- 
ant factor which is responsible for the improvement in 
exertional dyspnoea and in the recovery from the post- 
exercise oxyhaemoglobin desaturation. Exercise and 
postexercise-induced hypoxaemia in patients with COPD 
may occur with modest exercise and probably contribute to 
exercise limitation, and to pulmonary hypertension (27). 
Both drugs decrease the sustained postexercise oxyhaemo- 
globin desaturation and this effect is thought to be of some 
clinical benefit for the patients with COPD. 
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